The Biden administration announced Thursday that drug companies receiving research funding from HHS’ emergency response arm, the Administration for Strategic Preparedness and Response, will have to commit to a “fair price” – not more than they charge in other countries. Host Chelsea Cirruzzo talks with POLITICO health care reporter Robert King about the Biden administration's efforts to curb high prescription drug prices.
What’s next for rare disease treatments?
Behind the evolving overdose crisis
Newt's new view of NIH
Biden’s plan to expand HIPAA to protect abortion rights comes under bipartisan fire
CMS’ physician fee cut plan draws praise and criticism
How one red state boosted its public health budget
FDA approves first over-the-counter birth control. What’s next?
Sen. Sanders' line in the sand
A White House plan to tackle ‘Tranq Dope’
Major health care legislation looms
Biden proposes four-month cap on short-term health coverage
How the AMA chief plans to tackle pay and talk to Congress
CMS under fire from GOP for ignoring doctors’ advice on value-based care
The Medicare drug price negotiation plan is out
What’s next for the CDC post Walensky?
The future of Alzheimer’s treatment drugs
Abortion disputes in Congress stalls AIDS relief program
FDA’s first draft guidance for psychedelic research released
Medicare payment reform flounders on Capitol Hill
What the abortion landscape looks like now, one year after Roe
Create your
podcast in
minutes
It is Free